Publisher
Springer International Publishing
Reference37 articles.
1. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm.
2. Cooper DS, Anton B. The decade in clinical thyroid disease: an analysis of published literature. Thyroid. 2016;26(8):993–1003.
3. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.
4. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–32.
5. Hackshaw AK. A concise guide to clinical trials. 2nd ed. Wiley-Blackwell (BMJ Books); 2024.